Skip to main content

Month: January 2025

Taseko Announces 2024 Production Results and Amendment to Gibraltar Silver Stream

VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) — Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Taseko” or the “Company”) announces 2024 production from its 100% owned Gibraltar copper mine. Copper and molybdenum production for the year was 106 million pounds and 1.4 million pounds, respectively. Sales volumes for the year were 108 million pounds of copper and 1.4 million pounds of molybdenum. In late December, the Company closed a transaction with Osisko Gold Royalties to amend the Gibraltar silver steam agreement, increasing the attributable silver percentage from 87.5% to 100%. In exchange, Taseko has received an additional cash payment of US$12.7 million. Stuart McDonald, President & CEO of Taseko, commented, “Since completion of the planned major maintenance activities...

Continue reading

Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction

Divestment of Amwell Psychiatric Care intended to focus product portfolio on key growth initiatives Company reiterates guidance for 2024 BOSTON, Jan. 09, 2025 (GLOBE NEWSWIRE) — Amwell® (NYSE: AMWL), a global leader in digital care, today announced it has sold its Amwell Psychiatric Care (APC) business to Avel eCare, a national leading provider of clinician-to-clinician telehealth services. With the divestiture of APC, a virtual psychiatric care service that Amwell purchased in 2019, Amwell continues to sharpen its focus on key growth areas, driving greater efficiencies and fulfilling clients’ digital care ambitions. Throughout its nearly 20-year history, Amwell has continuously adapted to market demands by leveraging its technology and healthcare expertise to enable clients to deliver high-quality care. The company’s decision...

Continue reading

WALKER RIVER ANNOUNCES SIGNIFICANT GOLD INTERCEPTS INCLUDING 3.88 G/T OVER 77.72 METERS AT THE LAPON GOLD PROJECT

Vancouver, B.C. , Jan. 09, 2025 (GLOBE NEWSWIRE) — Walker River Resources Corp. (“Walker” or the “Company”) (TSX-V: WRR) is pleased to announce additional assay results from the 2024 reverse circulation (“RC”) drill program at the Lapon Canyon portion of the Lapon Gold Project, in Mineral County, Nevada, 60 km SE of Yerington, NV.Highlights    From To Width* GoldDrill Hole   (m) (m) (m) (g/t)LC-24-117   74.68 152.4 77.72 3.88including 77.72 94.49 16.77 12.09and 100.58 112.78 12.2 4.08LC-24-118   68.58 128.02 59.44 1.96including 68.58 74.68 6.10 8.17LC-24-110   41.15 74.68 33.53 2.70including 45.72 57.91 12.19 5.99LC-24-113   21.34 48.77 27.43 2.58including 25.91 32.00 6.09 4.13...

Continue reading

Taseko Announces 2024 Production Results

VANCOUVER, British Columbia, Jan. 09, 2025 (GLOBE NEWSWIRE) — Taseko Mines Limited (TSX: TKO; NYSE American: TGB; LSE: TKO) (“Taseko” or the “Company”) announces 2024 production from its 100% owned Gibraltar copper mine. Copper and molybdenum production for the year was 106 million pounds and 1.4 million pounds, respectively. Sales volumes for the year were 108 million pounds of copper and 1.4 million pounds of molybdenum. In late December, the Company closed a transaction with Osisko Gold Royalties to amend the Gibraltar silver steam agreement, increasing the attributable silver percentage from 87.5% to 100%. In exchange, Taseko has received an additional cash payment of US$12.7 million. Stuart McDonald, President & CEO of Taseko, commented, “Since completion of the planned major maintenance activities...

Continue reading

Freshworks to Announce Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

SAN MATEO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — Freshworks Inc. (NASDAQ: FRSH) will announce its financial results for the fourth quarter and full year ended December 31, 2024 following the close of market on Tuesday, February 11, 2025. Freshworks will host a live audio webcast beginning at 2:00 p.m Pacific Time / 5:00 p.m. Eastern Time that same day to discuss the company’s financial results and business highlights. Event: Freshworks Fourth Quarter and Full Year 2024 Financial Results Date: Tuesday, February 11, 2025Time: 2:00 p.m. PT / 5:00 p.m. ETAudio webcast: https://ir.freshworks.com A webcast replay will be accessible from the Freshworks investor relations website at https://ir.freshworks.com. The press release will be accessible from the Freshworks investor relations website prior to the commencement of the event. About...

Continue reading

RAPT Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time. To access the live webcast or subsequent archived recording of the company presentation, please visit the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations. About RAPT Therapeutics, Inc.RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing...

Continue reading

Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

The panel will discuss the value proposition for investing in women’s health. J.P. Morgan is hosting a three-panel women’s health series at this year’s conference to highlight the importance of innovation and growing visibility around women’s health. SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, announced today that Sabrina Martucci Johnson, President and CEO of Daré Bioscience, will be speaking on the ARPA-H | Investing in Women’s Health panel during the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The panel will be on Tuesday, January 14th at 2:15 p.m. PT and will be followed by two additional panels focused on women’s health, The Future of Women’s Health Care and Flow of Capital...

Continue reading

Enphase Energy Expands in Latin America with Launch of IQ8 Microinverters in Colombia, Panama, and Costa Rica

FREMONT, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world’s leading supplier of microinverter-based solar and battery systems, today announced that it is expanding in Latin America with the launch of IQ8P™ Microinverters, with peak output AC power of 480 W, for residential and commercial applications in Colombia, Panama, and Costa Rica to support newer high-powered solar modules. Enphase is working with installers and distributors throughout Latin America, including the recent launch of IQ8™ Microinverters in the Caribbean, as well as ongoing operations in Brazil, Puerto Rico, and Mexico. IQ8 Microinverters are designed to maximize energy production and can manage a continuous DC current of 14 amperes, supporting higher-powered solar...

Continue reading

Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings

Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer’s Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer’s disease (AD) Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025 NEWTON, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) — Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that the Journal of Prevention of Alzheimer’s Disease...

Continue reading

EagleBank Adds New Market Executive and Two Relationship Managers to C&I Lending Team

Addition of experienced bankers in the DMV region complements EagleBank’s C&I growth strategy BETHESDA, Md., Jan. 09, 2025 (GLOBE NEWSWIRE) — EagleBank (NASDAQ: EGBN), one of the largest community banks in the Washington, D.C. area, today announced that Bryan Pynchon will join the Bank as a C&I Market Executive for Maryland and Ian Joseph and Andrew Brkic as Relationship Managers (RMs) under Pynchon’s leadership, as of January 6, 2025. In their respective roles, the new team members will work to advance EagleBank’s goal of expanding its robust, diverse, and stable C&I portfolio. “The talent that we put in front of clients is a point of pride for Eagle and adding Bryan, Ian and Andrew to the team will even further enhance our position as the go-to commercial lender in the Greater Washington community,” said Evelyn...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.